机械性血栓切除术与药物机械性导管定向溶栓治疗髂股深静脉血栓的比较:12个月临床结局的倾向性评分匹配探索性分析
本回顾性队列分析将多中心前瞻性MT ClotTriever Outcomes注册研究与随机试验PCDT组的倾向性评分匹配亚组进行比较,共匹配130对髂股深静脉血栓患者。结果显示,MT较PCDT血栓负担减少更明显(Marder评分降低91.0% vs 67.7%,p<.001),12个月无血栓后综合征比例更高(83.1% vs 63.6%,p=.007),且单次治疗率更高、住院时间更短、ICU使用更少。
要点
- MT组Marder评分降低91.0%,PCDT组降低67.7%(p<.001)。
- 12个月无血栓后综合征比例MT组83.1%,PCDT组63.6%(p=.007)。
- MT组单次治疗率97.7%,PCDT组26.9%(p<.001)。
核心结论
- 与PCDT相比,MT与围手术期血栓减少更多、术后护理更高效以及12个月时髂股静脉疾病症状和体征改善相关。
研究设计与样本
- 回顾性队列分析,比较多中心前瞻性MT ClotTriever Outcomes注册研究和随机试验Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter Directed Thrombolysis的PCDT组的倾向性评分匹配亚组。
- 排除双侧DVT、症状持续时间大于四周、孤立股-腘病变或病例数据不完整的患者。
- 髂股DVT患者按10个基线协变量进行1:1倾向性评分匹配,协变量包括种族、性别、年龄、体重指数、治疗腿、既往血栓栓塞、Marder评分、症状持续时间、诱发性深静脉血栓状态和Villalta评分。
- 匹配后形成130对患者,MT组与PCDT组基线特征无显著差异。
主要发现
- MT组Marder评分降低91.0%,PCDT组降低67.7%(p<.001)。
- 12个月时无血栓后综合征的患者比例MT组为83.1%,PCDT组为63.6%(p=.007)。
- 辅助支架或静脉成形术率无差异(p=.27)。
- 单次治疗率MT组为97.7%,PCDT组为26.9%(p<.001)。
- 术后平均住院过夜数MT组为1.81,PCDT组为3.46(p<.001);术后ICU使用率MT组为2.3%,PCDT组为52.8%(p<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare thrombus removal and residual venous symptoms and signs of disease following interventional treatment of iliofemoral deep vein thrombosis (DVT) with mechanical thrombectomy (MT) and pharmacomechanical catheter directed thrombolysis (PCDT). METHODS: Retrospective cohort analysis of propensity score matched subgroups from the multicentre prospective MT ClotTriever Outcomes registry and the PCDT arm of the randomised Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter Directed Thrombolysis trial. Patients with bilateral DVT, symptom duration greater than four weeks, isolated femoral-popliteal disease, or incomplete case data were excluded. Patients with iliofemoral DVT were propensity score matched (1:1) on 10 baseline covariables, including race, sex, age, body mass index, leg treated, prior thromboembolism, Marder score, symptom duration, provoked deep vein thrombosis status, and Villalta score. Reduction in post-procedure thrombus burden (i.e., Marder scores), assessment of venous symptoms and signs (i.e., Villalta scores) at 12 months, and healthcare resource utilisation were compared between subgroups. RESULTS: Propensity score matching resulted in 130 patient pairs with no significant differences in baseline characteristics between the MT and PCDT groups. MT was associated with a greater reduction in Marder scores (91.0% vs. 67.7%, p < .001), and a greater proportion of patients at 12 months with no post-thrombotic syndrome (83.1% vs. 63.6%, p = .007) compared with matched patients receiving PCDT. No differences in rates of adjunctive stenting or venoplasty were identified (p = .27). Higher rates of single session treatment were seen with MT (97.7% vs. 26.9%, p < .001), which also showed shorter mean post-procedure hospital stays (1.81 vs. 3.46 overnights, p < .001), and less post-procedure intensive care unit utilisation (2.3% vs. 52.8%, p < .001). CONCLUSION: Compared with PCDT, MT was associated with greater peri-procedural thrombus reduction, more efficient post-procedure care, and improved symptoms and signs of iliofemoral vein disease at 12 months.
引用
- Abramowitz S, Bunte MC, Maldonado TS, et al. Mechanical Thrombectomy vs. Pharmacomechanical Catheter Directed Thrombolysis for the Treatment of Iliofemoral Deep Vein Thrombosis: A Propensity Score Matched Exploratory Analysis of 12 Month Clinical Outcomes. Eur J Vasc Endovasc Surg. 2023. PMID: 37981003. doi:10.1016/j.ejvs.2023.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。